BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company and its officers’ possible violations of federal securities laws.
On November 4, 2019, Plainview LLC (“Plainview”) published a report questioning the safety and efficacy of Fibrogen’s lead product candidate, Roxadustat.
On this news, Fibrogen’s stock price fell $3.01 per share, or nearly 8%, to close at $37.01 per share on November 4, 2019, thereby injuring investors.
If you purchased FibroGen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.